1) Chhablani J, Kozak I, Pichi F, et al. Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina 2015;35:2489-97.
2) Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010;30:100-6.
3) Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011;152:784-92.e2.
4) Chung YR, Kim JW, Song JH, et al. Twelve-month efficacy of intravitreal bevacizumab injection for chronic, atypical, or recurrent central serous chorioretinopathy. Retina 2019;39:134-42.
5) Schaal KB, Hoeh AE, Scheuerle A, et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009;19:613-7.
6) Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010;35:91-8.
7) Inoue M, Kadonosono K, Watanabe Y, et al. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. Ophthalmologica 2011;225:37-40.
8) Broadhead GK, Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2015;253:979-81.
9) Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol 2015;99:848-52.
10) Aydin E. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. J Ocul Pharmacol Ther 2013;29:10-3.
11) Seong HK, Bae JH, Kim ES, et al. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica 2009;223:343-7.
12) Torres-Soriano ME, García-Aguirre G, Kon-Jara V, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008;246:1235-9.
13) Kweon EY. Factors influencing the effect of the intravitreal bevacizumab injection in patients with central serous chorioretinopathy. J Korean Ophthalmol Soc 2014;55:391-5.
14) Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83.
15) Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol 2012;96:1157-8.
16) Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2012;96:1-2.
17) Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96:14-20.
20) Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010;149:361-3.
22) Kim M, Lee SC, Lee SJ. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica 2013;229:152-7.
24) Tekin K, Sekeroglu MA, Cankaya AB, et al. Intravitreal bevacizumab and ranibizumab in the treatment of acute central serous chorioretihopathy: a single center retrospective study. Semin Ophthalmol 2018;33:265-70.
25) Koh KM, Kim JY, Kim JW, Choi MJ. The efficacy of intravitreal bevacizumab injection in patients with acute central serous chorioretinopathy. J Korean Ophthalmol Soc 2012;53:781-5.
28) Tekin K, Cakar Ozdal P, Gulpamuk B, Yasin Teke M. Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: short term results. Arch Soc Esp Oftalmol (Engl Ed) 2018;93:315-23.
29) Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016;123:1351-9.
30) Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol 2016;134:95-9.
31) Lotfy A, Solaiman KAM, Abdelrahman A, Samir A. Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 2018;38:1795-800.
32) Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin- 6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009;116:87-93.
33) Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005;112:806-16.
34) Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010;30:1465-71.
35) Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 2011;31:1937-43.
36) Bodla MA, Bodla AA, Kazmi SM, Moazzam A. Effects of intravitreal aflibercept in patients with central serous chorioretinopathy. Pak J Ophthalmol 2020;36:402-7.
37) Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol 2014;7:167-80.
38) Hwang H, Kim JY, Kim KT, et al. Flat irregular pigment epithelium detachment in central serous chorioretinopathy: a form of pachychoroid neovasculopathy? Retina 2020;40:1724-33.